For Q3 FY2025 (ended September 30, 2025), Avalo Therapeutics reported zero revenue, a 100% year-over-year decline. Net loss was $19.63 million for the trailing twelve months ended March 31, 2026, with operating loss of $20.90 million. Diluted EPS was -$0.98, improving 21.6% year-over-year.
•Revenue was $0, down 100% YoY.
•Net loss of $19.63 million (TTM) widened 49.3% YoY.
•Operating loss of $20.90 million (TTM) widened 42.5% YoY.
•Diluted EPS of -$0.98 improved 21.6% YoY.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
Avalo Therapeutics, Inc., a clinical stage biotechnology company develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. Incorporated in 2011 and headquartered in Wayne, Pennsylvania, Avalo Therapeutics was formerly known as Cerecor Inc. before rebranding in August 2021.
Avalo Therapeutics, Inc. is a clinical stage biotechnology company focused on developing IL-1β-based treatments for immune-mediated inflammatory diseases. Its lead product candidate is AVTX-009, a humanized monoclonal antibody that binds to interleukin-1β, which is currently in a Phase 2 clinical trial for treating inflammatory diseases. The company operates in the United States and is dedicated to addressing unmet medical needs in the field of inflammation.
Where is Avalo Therapeutics (AVTX) listed and what currency is used?
Avalo Therapeutics is listed on the Nasdaq Capital Market (NasdaqCM) under the ticker symbol AVTX. The company trades in U.S. dollars (USD), as it is headquartered in the United States and its securities are traded on a U.S. exchange. Investors can buy and sell AVTX shares through brokerage accounts that have access to Nasdaq.
What sector and industry does Avalo Therapeutics (AVTX) belong to?
Avalo Therapeutics operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on researching and developing novel therapies, particularly in the area of immune-mediated inflammatory diseases. The company's work involves advanced biological approaches, such as monoclonal antibodies, to target specific pathways in the immune system.
Where is Avalo Therapeutics (AVTX) headquartered and what is its history?
Avalo Therapeutics is headquartered in Wayne, Pennsylvania, United States. The company was incorporated in 2011 and was formerly known as Cerecor Inc. before rebranding to Avalo Therapeutics in August 2021. This rebranding reflected a strategic shift in focus toward developing IL-1β-based treatments for inflammatory diseases.
What is the main product candidate of Avalo Therapeutics (AVTX)?
Avalo Therapeutics' main product candidate is AVTX-009, a humanized monoclonal antibody designed to bind to interleukin-1β (IL-1β), a key protein involved in inflammation. AVTX-009 is currently in Phase 2 clinical trials for the treatment of immune-mediated inflammatory diseases. The company is developing this therapy to address conditions where IL-1β plays a central role in disease pathology.